title: [Targeting studies of humanized scFv25 fusing to TNFalpha against hepatocellular carcinoma].
abstract: OBJECTIVE
  To obtain humanized engineering bifunctional antibody, which has potentialities for clinical application.
  
  
  METHODS
  Humanized anti-human hepatocellular carcinoma (HCC) single chain fragment (hscFv25) was linked with human TNF-alpha gene to form anti-HCC bifunctional antibody, then it was subcloned into prokaryotic GST fusion expression vector pGEX 4T-1 and expressed in the host E.coli. Indirect immunofluorescent staining was performed on HCC cell smearing slides in order to evaluate the activity of the purified aim protein, then MTT trial to evaluate the cytotoxicity of hscFv25-TNFalpha to SMMC-7721, finally primary tumor regression trial in nude mice bearing HCC to evaluate the targeting therapeutic value of hscFv25-TNFalpha.
  
  
  RESULTS
  The hscFv25-TNFalpha had the similar specificity to parental antibody HAb25 for SMMC-7721 antigen. One hour predisposed MTT trial in control with parental antibody HAb25 affirmed that hscFv25-TNFalpha was cytotoxic to targeted cell SMMC-7721 with the IC(50) to be 7.1 microg/ml. The cytotoxicity can be inhibited by parental antibody HAb25. This indicated that the cytotoxicity of hscFv25-TNFalpha to targeted cell is antibody-mediated selective cytotoxicity. The tumor regression trial to the 3mm HCC xenografts in nude mice showed that hscFv25-TNFalpha had assured targeting cytotoxicity and the efficiency was nearly up to 3/3 (1/3 complete remission, 2/3 partial remission). The cytotoxicity of the hscFv25-TNFalpha was better than that of TNFalpha, whose efficiency was only 2/3 and without complete remission.
  
  
  CONCLUSIONS
  hscFv25-TNFalpha is an anti-HCC bi-functional antibody which has potentialities for clinical application.
authors.affiliation: Institute of Biotechnology, Beijing 100071, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Sun
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: Q
authors.initials: Q
authors.lastname: Yuan
authors.forename: W
authors.initials: W
authors.lastname: Yu
authors.forename: C
authors.initials: C
authors.lastname: Huang
authors.forename: L
authors.initials: L
authors.lastname: Ma
authors.forename: J
authors.initials: J
authors.lastname: Yu
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D006801:Humans; D007128:Immunoglobulin Fragments / Q000627:therapeutic use*; D008114:Liver Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D018033:Antibodies, Bispecific; D000912:Antibodies, Neoplasm; D007128:Immunoglobulin Fragments; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; C055966:immunoglobulin Fv